Greg Durm, Md

This study is for people with stage I non-small cell lung cancer who have had their tumor surgically removed. It compares receiving the immunotherapy drug pembrolizumab every 6 weeks for about a year versus simply being watched (observation). The goal is to see if pembrolizumab c…